RE:Worth a Buy Yet? Management has actually been doing a good job IMHO but I am judging that based on the progress they are making with such things as; product rollouts, partnerships and expansion of the business into new markets... definately not using the SP as a basis for my own assessement of the management team.
As for capitial raise etc, the company, like all the major players, is not profitable at this point so until they turn cash flow positive they may at times need to raise more money to fund new expansion, new products etc. As long as the capitial raise produces more revenue for the operation at an acceptable margin (HEXO seems to favor 40%) then it's a win for investors who hold long for those incremental revenues to show up on the books.
The biggest challenge most have (again... IMHO) is that they invest thinking they will be rich overnight rather than have the patience for the organization to grow and start producing those stronger QTR reports.
Hope that helps.
Q
CGYY80 wrote:
Haven't held hexo since the Hydropothecary days a few years ago. Redecan revenue puts HEXO up with Canopy and Tilray in terms of revenue, at a fraction of the market cap of the bigger players. My biggest concern is that Sebastian has more tricks up his sleeve to absolutely burn shareholders more so than he's already done - specifically the endless raises and dilution.
I'm conflicted, seems undervalued but I also think the folks at the helm are clueless here. Thoughts?